

Recruiting Patients With Breast Cancer and Their Families to Behavioral Research in the Post-HIPAA Period

Deborah J. Bowen, PhD, Jesse R. Fann, MD, MPH, M. Robyn Andersen, PhD, Isaac C. Rhew, MPH, Julie R. Gralow, MD, Frances M. Lewis, PhD, RN, Julie R. Hunt, PhD, Melanie Palomares, MD, MS, Carol M. Moinpour, PhD, and Donna P. Ankerst, PhD

Purpose/Objectives: To describe a process for, response rates of, and indicated interest in recruiting patients with breast cancer and their spouses and family members from a clinical setting into behavioral and psychiatric research studies since the Health Insurance Portability and Accountability Act (HIPAA) regulations have taken effect.

Data Sources: Published articles, books and book chapters, MEDLINE®, government agency information and HIPAA regulatory Web sites, and survey data.

Data Synthesis: Response rates among the three target groups—patients, spouses and partners, and female first-degree relatives—were 77%, 95%, and 88%, respectively. Interest was high in the three target groups, with 77%, 87%, and 65% of responding patients, spouses and partners, and female first-degree relatives, respectively.

Conclusions: Taken together, these data indicate that high participation rates can be expected from patients with breast cancer and their families in clinical settings.

Implications for Nursing: Regulations pose barriers to patient and family recruitment, but thoughtful systems actually can improve rates of recruitment.

Key Points . . .

- Recruiting patients with cancer and their family members into research, specifically randomized trials, requires multiple steps.
- Most patients and families will provide background information to determine study eligibility.
- Many patients and families are interested in behavioral research.

1997; Newcomb, Love, Phillips, & Buckmaster, 1990; Taylor, Margolese, & Soskoline, 1984).

Furthermore, clinical data now are more difficult to incorporate into research activities. The Health Insurance Portability and Accountability Act (HIPAA) of 1996 described how clinical entities can use or disclose protected health information, including for research purposes. The regulations affect how

Recruiting patients from clinical settings into cancer clinical trials is a difficult but essential element of the success of the National Cancer Institute's efforts to reduce cancer mortality. Overall, less than 50% of patients with cancer participate in treatment trials nationwide (Beskow, Sandler, & Weinberger, 2006; Elting et al., 2006; Gotay, 1991; Heiney et al., 2006). Even institutions with appropriate trials available that are dedicated to recruiting patients for clinical and behavioral trials often reported that recruitment rates are modest, varying from 19%–53% (of clinically eligible patients older than age 35) (Hunter et al., 1987; Lee, Marks, & Simpson, 1980; Spiro, Gower, Evans, Facchini, & Rudd, 2000). Low recruitment yields into clinical trials commonly are reported among patients with cancer (Ashing-Giwa, 2005; Ashing-Giwa, Padilla, Tejero, & Kim, 2004; Hunter et al.; Hutchins, Unger, Crowley, Coltmant, & Albain, 1999; Sears et al., 2003). Recruitment yields in those studies have ranged from 16%–36%. Modest rates of recruitment occur for several reasons. Key barriers to patient participation in clinical trials often are provider-related, including the time commitment involved, obtainment of informed consent, and intrusion of the study on the physician-patient relationship (Benson et al., 1991; Lovato, Hill, Hertert, Hunninghake, & Probstfield,

Deborah J. Bowen, PhD, is a joint member at the Fred Hutchinson Cancer Research Center in Seattle, WA; Jesse R. Fann, MD, MPH, is an associate professor in the School of Medicine at the University of Washington (UW) in Seattle; M. Robyn Andersen, PhD, is an assistant member of the division of Public Health Sciences at the Fred Hutchinson Cancer Research Center; Isaac C. Rhew, MPH, is a predoctorate research associate in the Department of Epidemiology at UW in Seattle; Julie R. Gralow, MD, is an associate professor in the School of Medicine at UW in Seattle; Frances M. Lewis, PhD, RN, is a professor in the School of Nursing at UW in Seattle; Julie R. Hunt, PhD, is a senior staff scientist in the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center; Melanie Palomares, MD, MS, is an assistant professor in medical oncology in the Division of Population Sciences, a staff physician for the Cancer Screening and Prevention Program, and a member of the Comprehensive Cancer Center at the City of Hope in Duarte, CA; Carol M. Moinpour, PhD, is an associate member of the Fred Hutchinson Cancer Research Center; and Donna P. Ankerst, PhD, is an associate research professor in the Health Science Center at the University of Texas in San Antonio and a research scientist at the University of Munich in Germany. This research was supported by a grant (CA82894) from the National Cancer Institute and by Fred Hutchinson Cancer Research Center developmental research funds. (Submitted March 2007. Accepted for publication April 3, 2007.)

Digital Object Identifier: 10.1188/07.ONF.1049-1054